David Rodrigues e Daniel Pinto falam sobre o artigo Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality – The CAP Randomized Clinical Trial.
Deixem comentário, entrem na discussão!

Artigo em análise:

Martin RM, Donovan JL, Turner EL, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality – The CAP Randomized Clinical Trial. JAMA. 2018;319(9):883–895. doi:10.1001/jama.2018.0154

Ensaios prévios:

PLCO – Andriole GL, Crawford ED, Grubb RL, et al. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. JNCI Journal of the National Cancer Institute. 2012;104(2):125-132. doi:10.1093/jnci/djr500.

ERSPC – Schröder FH, Hugosson J, Roobol MJ, et al. The European Randomized Study of Screening for Prostate Cancer – Prostate Cancer Mortality at 13 Years of Follow-up. Lancet. 2014;384(9959):2027-2035. doi:10.1016/S0140-6736(14)60525-0.

Revisão da Cochrane – Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.

Sobrediagnóstico – editorial no BMJ Evidence

United States Preventive Services Task Force – rastreio do cancro da próstata

Direcção-Geral da Saúde – Prescrição e determinação do PSA